Navigation Links
Metabolex Names Zhao, Martin to Executive Posts
Date:7/7/2008

HAYWARD, Calif., July 7 /PRNewswire/ -- Metabolex, Inc., a biopharmaceutical company focused on the discovery and development of proprietary new medicines for the treatment of metabolic diseases, announced that it has promoted Zuchun 'Spring' Zhao to Vice President of Chemical Sciences, and Robert Martin to Vice President of Project and Portfolio Management.

"These appointments represent a significant development in our company in support of our expanding research and clinical pipeline," said Charles McWherter, Ph.D., Senior Vice President of Research and Preclinical Development. "Spring brings a winning combination of creativity in medicinal chemistry along with strong credentials in all aspects of drug discovery and development." Dr. McWherter continued, "Rob is an exceptional asset to Metabolex. He comes with the focus on execution of a biotech but with the savvy of his formative years in pharmaceutical research. Rob is a real master of integrating portfolio strategy with practical operational alternatives."

Dr. Zhao joined Metabolex in 2000 as the head of chemistry, and was instrumental in building the chemistry department. Over the past eight years, he has served in a variety of operational and leadership roles, most recently leading drug discovery projects from lead identification to clinical trials. Earlier in his career, Dr. Zhao worked at Berlex where he contributed to the advancement of several compounds. Dr. Zhao holds a Ph.D. from the University of California Los Angeles, is an inventor on several patents and has published numerous scientific papers in the field of drug discovery.

Dr. Martin joined Metabolex in 2004 and has served the company in a variety of preclinical development and project management positions, most recently as Senior Director of Portfolio Management. He has played a key role in a number of projects in the Metabolex pipeline. Prior to joining the company, he spent ten years with Roche where in his last position -- in the research strategy group -- he focused on improving the productivity of the global research organization. Dr. Martin holds a Ph.D. from the University of California Davis.

About Metabolex

Metabolex is a privately-held biopharmaceutical company focused on the discovery and development of proprietary new medicines for the treatment of metabolic diseases, with an emphasis on type 2 diabetes. Metabolex has drawn on its deep understanding of diabetes to create a large database of genes involved in diabetes and to build a rich pipeline of product candidates and drug discovery targets. The company has four clinical-stage compounds: MBX-102/JNJ 39659100, which has completed three Phase 2 trials; MBX-2044, which has completed a Phase 2a trial; MBX-8025, currently being studied in a Phase 2 trial in patients with dyslipidemia; and MBX-2982, currently being studied in a Phase 1 trial. Ortho-McNeil, Inc. has the exclusive right to develop and commercialize MBX-102/JNJ 39659100. For additional information about Metabolex and its development pipeline, visit http://www.metabolex.com.


'/>"/>
SOURCE Metabolex, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Metabolex Appoints Donald Hill as Chief Financial Officer
2. KGI Names Kerry Howell Vice President for Advancement
3. Vical Names Andrew de Guttadauro Vice President, Corporate Development
4. IDM Pharma Names Dr. Jeffrey W. Sherman Chief Medical Officer and Senior Vice President of Research and Development
5. Magellan Biosciences Names Steven E. Diamond, PhD, Chief Scientific Officer
6. CryoLife Names Philip Theodore as Vice President, General Counsel
7. Genstar Names Michael Hurt to Its Strategic Advisory Board
8. PPD Names Daniel Darazsdi as Chief Financial Officer
9. Society of Laproendoscopic Surgeons Names Starion Instruments 2007 Innovator of the Year
10. Cadence Pharmaceuticals Names Malvina Laudicina Vice President of Regulatory Affairs and Quality Assurance
11. Mpex Pharmaceuticals Names Dr. Jeffery Loutit as Chief Medical Officer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/27/2016)... ... April 27, 2016 , ... Cambridge Semantics, the ... technology, today announced that it has been named to The Silicon Review’s “20 Fastest ... and other markets, Cambridge Semantics serves the needs of end users facing some of ...
(Date:4/27/2016)... and RESEARCH TRIANGLE PARK, N.C. , ... UTHR ) announced today that Martine Rothblatt ... Therapeutics will provide an overview and update on the ... Annual Health Care Conference. The presentation will ... a.m. Eastern Time, and can be accessed via a ...
(Date:4/27/2016)... ... April 27, 2016 , ... Global Stem Cells Group CEO ... is the founder of GSCG affiliate Kimera Labs in Miami. , In 2004, Ross ... stem cell transplantation for hematologic disorders and the suppression of graft vs. host disease ...
(Date:4/26/2016)... (PRWEB) , ... April 26, 2016 , ... ... today announced that Ardy Arianpour has joined the company as Chief Business Officer. ... experience bringing innovative genomic technologies to market, was most recently Chief Commercial Officer ...
Breaking Biology Technology:
(Date:4/13/2016)... CHICAGO , April 13, 2016  IMPOWER physicians ... are setting a new clinical standard in telehealth ... By leveraging the higi platform, IMPOWER patients can ... weight, pulse and body mass index, and, when they ... quick and convenient visit to a local retail location ...
(Date:3/22/2016)... 2016 According to ... for Consumer Industry by Type (Image, Motion, Pressure, ... & IT, Entertainment, Home Appliances, & Wearable ... 2022", published by MarketsandMarkets, the market for ... USD 26.76 Billion by 2022, at a ...
(Date:3/15/2016)... 15, 2016 --> ... Transparency Market Research "Digital Door Lock Systems Market - Global ... 2023," the global digital door lock systems market in terms ... and is forecast to grow at a CAGR of 31.8% ... and medium enterprises (MSMEs) across the world and high industrial ...
Breaking Biology News(10 mins):